Annovis Bio raises $3M via registered direct offering of 316,455 shares at $9.48/share

Annovis Bio, Inc.

Sold 316,455 common shares at $9.48 each for $3.0M gross proceeds under effective Form S-3 shelf registration.
30-day post-closing lock-up restricts new equity issuances, warrant amendments, registration filings, and variable-rate deals.
Closing contingent on NYSE listing of the offered shares; expected promptly after conditions satisfied.
Buyer may sell shares during pre-settlement period and remains unconditionally bound to purchase at closing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Annovis Bio, Inc. entered into Securities Purchase Agreement with an institutional investor valued at $3,000,000 (effective 2024-03-21).

Action: entry
Agreement: equity purchase
Counterparty: an institutional investor
Value: $3,000,000
Effective: 2024-03-21

Exact text from the filing

On March 21, 2024, Annovis Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Buyer”).

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-037406

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.